Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 911 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Cancer in My Community: Obstacles to Caring for People With Cancer... November 23, 2020 The National Parks Service Still Hasn’t Fixed It’s Sexual Harassment Problem January 6, 2022 Pastor Opens Homeless Shelter And Moves In To Raise Money For... December 29, 2021 Pembrolizumab Plus Axitinib Outperforms Sunitinib in Patients with Metastatic Renal Cell... November 21, 2020 Load more HOT NEWS Marc Cuban’s Cost Plus Drug Company: A Potential Gold Mine for... How targeted screening can help the NHS save lives from lung... A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year... Tips from Your Cancer Care Team – Coping with Treatment During...
